Related references
Note: Only part of the references are listed.Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis
Mark C. Genovese et al.
JOURNAL OF RHEUMATOLOGY (2016)
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Christopher E. M. Griffiths et al.
LANCET (2015)
Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis
H. Saeki et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis
Kenneth B. Gordon et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Mark C. Genovese et al.
ARTHRITIS & RHEUMATOLOGY (2014)
IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis
James G. Krueger et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Anti-Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
Craig Leonardi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Share Paper
